Researchers identify vulnerability for glioblastoma subtypes This type of research is the key to finding the cure. All of the treatments that have failed phase 2 and 3 trials should be retested to try to figure out why there was enough success in the phase 1 trial to justify the phase 2, then having the subsequent trial fail. Most likely there is a subtype of tumor that IS sensitive to the treatment.
